The potential treatments include ivermectin, methylene blue, glucagon-like peptide-1 receptor agonists, and low-dose naltrexone.
Valerie Richards, PharmD
Advertisement
Articles by Valerie Richards, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
New CKD Outcome Set Tells Pharmacists What to Measure
2
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
3
The PBM Reform Clock Is Running to 2028—Here's What Independent Pharmacies Should Do
4
GLP-1s and the HCM–Sleep Apnea–Obesity Connection
5